AAVivo, Inc. to Present Precision AAV Capsid Engineering (PACE) Platform for In Vivo CAR-T Therapy at BIOHK2025

HOUSTON, Sept. 8, 2025 /PRNewswire/ — AAVivo, Inc., a pioneering biotechnology developing novel, precision targeted biotherapeutics to enable in vivo generation of CAR-T cells, today announced that Chief Technology Officer & Founder, Haifeng Chen, Ph.D., will present at BIOHK2025, the Hong Kong International Biotechnology Conference & Exhibition.

In a presentation titled, “PACE: A Breakthrough AAV Capsid Engineering Platform Enabling In Vivo CAR-T Therapy and Precision Gene Delivery,” Dr. Chen will discuss AAVivo’s PACE platform, which enables the transformation of non-targeted AAV vectors into precise and cell specific gene delivery vectors. PACE is a core component of AAVivo’s IntelligentAAV (iAAV) platform, which is designed to allow rapid development of precision biotherapies that can be produced by a patient’s body for potent, long-term disease control. PACE-modified AAV vectors therapies produced by the platform can deliver diverse payloads to specific tissues or cell types to either enhance immune cell function, redirect cells in situ to produce targeted therapies locally and persistently, or to kill malignant cells directly.

About AAVivo, Inc.
AAVivo, Inc. is a biotechnology innovator advancing precision-targeted biotherapeutics through its proprietary iAAV-based platform. By harnessing a suite of patented technologies, AAVivo enables the in vivo generation of CAR-T cells, offering a transformative alternative to traditional CAR-T therapies. The company’s cutting-edge platform includes: 

• BAC-to-AAV Technology, enabling large-scale, cost-effective AAV manufacturing
• Precision AAV Capsid Engineering (PACE), delivering highly specific cell targeting for enhanced therapeutic outcomes
• Selective toxin packaging (SToP) platform with microRNA safety shield, ensuring safe delivery of potent therapeutic genes

Together, these innovations provide higher yields, enhanced potency without the need for lymphodepletion, and superior scalability, unlocking the potential of AAV vectors across diverse indications. AAVivo’s development pipeline, which includes AVO-100, the company’s lead product for B cell malignancies, as well as AVO-200 and AVO-300 for solid tumors, positions the company as a leader in the rapidly growing gene therapy market, offering investors a unique opportunity to support a scalable, high-impact biotech platform. AAVivo is headquartered in Houston, Texas. For more information, visit https://aavivo.com/.

Contact
Tiberend Strategic Advisors, Inc.
Investor Relations
Jon Nugent
205-566-3026
[email protected]  

Media Relations
Casey McDonald
646-577-8520
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/aavivo-inc-to-present-precision-aav-capsid-engineering-pace-platform-for-in-vivo-car-t-therapy-at-biohk2025-302549371.html

SOURCE AAVivo, Inc.